The Business Journals

Atlas Venture's newest stab at an antibiotics biotech comes out of stealth

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Recent federal legislation designed to encourage the ...
STAT

Biotech VC raises $400 million ‘opportunity’ fund in sign of possible industry rebound

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
MarketWatch

HealthTech Bridge Launches to Accelerate Clinical Validation and U.S. Market Readiness for International HealthTech Innovators

The MarketWatch News Department was not involved in the creation of this content. FAYETTEVILLE, Ark., March 5, 2026 /PRNewswire/ -- HTA and Venture Atlas Labs announced a new commercial and clinical ...
The Business Journals

Atlas Venture raises $400M to invest in later-stage biotechs

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Cambridge biotech venture ...
Benzinga.com

ATLAS VENTURE PARALLEL FUND V-A C V's Net Worth

ATLAS VENTURE PARALLEL FUND V-A C V does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include ALNYLAM ...
The Boston Globe

Biotech VC raises $400 million ‘opportunity’ fund in sign of possible industry rebound

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Prominent biotech VC firm Atlas Venture ...